Transgenomic last week said that pharmaceutical companies’ growing need for its pharmacogenomic research services helped lift the firm’s fourth-quarter revenue and profit. Moving forward, the company plans to expand these collaborations to extend the applications of its Wave instruments and to access biomarkers that it can eventually develop into diagnostics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.